sultamicillin and Genital-Diseases--Female

An open comparative and multicentric trial was carried out to assess the activity of sulbactam ampicillin combination against no treatment, as a prophylactic agent of post-surgical infection in ob-gyn practice. 100 patients were included in the trial and distributed in two groups. sulbactam/ampicillin 0.5/1.0 g, i.v. was administrated during the surgery and the dose was repeated 6 h. later. No cases of post-surgical infection was detected in the group of sulbactam/ampicillin, while 4 cases were observed in the no treatment group. Sulbactam/ampicillin is an effective and well tolerated antimicrobial agent in the prophylaxis of post-surgical infections.

Topics: Adolescent; Adult; Aged; Ampicillin; Drug Therapy, Combination; Female; Genital Diseases, Female; Humans; Middle Aged; Postoperative Care; Pregnancy; Pregnancy Complications; Premedication; Prospective Studies; Sulbactam; Surgical Wound Infection

A total of 40 adult females were studied suffering from different obstetric and gynaecological infections. In 30 patients two 375 mg sultamicillin tablets were taken twice daily, whereas 10 patients received one 375 mg sultamicillin tablet twice daily. The duration of treatment ranged from 5 to 12 days, with a mean of 6.6 days. Cure or improvement was reported in 35 (87.5%) cases, whereas five (12.5%) patients did not respond to therapy. Of the 61 pathogens isolated before treatment, 56 (91.8%) were eradicated. Clinical tolerability of the therapy was excellent, with no adverse effects being observed in any of the studied patients. The absence of significant differences between the mean values of blood count, hepatic and renal function tests performed before and after treatment confirmed the safety of treatment. It is concluded that sultamicillin is a suitable and useful additional antibiotic therapy for the treatment of obstetric and gynaecological bacterial infections.

Topics: Administration, Oral; Adolescent; Adult; Aged; Ampicillin; Bacterial Infections; Drug Administration Schedule; Drug Therapy, Combination; Female; Genital Diseases, Female; Humans; Middle Aged; Premedication; Sulbactam

A therapeutic interchange program based on microbial patterns within an institution is described. A change in anaerobic susceptibility patterns, increased prevalence of enterococcal infections, and cost factors provided the rationale for the therapeutic interchange of ampicillin-sulbactam for cefoxitin. Ampicillin-sulbactam was recommended for prophylaxis in intraabdominal or gynecological surgery as well as for treatment for gynecological infections. Cefoxitin was restricted to penicillin-allergic patients and women who were pregnant or breast-feeding. The transition from cefoxitin to ampicillin-sulbactam proceeded smoothly as a result of preliminary education of pharmacists and physicians. Pharmacists participated in continuing-education programs and received concise guidelines for the interchange and follow-up instructions; physicians learned of the program from the drug newsletter published by the pharmacy department. Three months after the program began, only one physician was resistant to the interchange. After the program began, 11 antimicrobials, including cefoxitin, were used less frequently and ampicillin-sulbactam use increased. No adverse clinical consequences from the interchange were detected. A therapeutic interchange program based on institution-specific microbial patterns and educational efforts by the pharmacy department produced a change in physician prescribing.

Topics: Ampicillin; Bacteria, Anaerobic; Cefoxitin; Drug Costs; Drug Therapy, Combination; Female; Genital Diseases, Female; Humans; Microbial Sensitivity Tests; Premedication; Sulbactam; Therapeutic Equivalency

Estimates were carried out on the clinical and bacteriological efficacy of an intramuscular combination of sulbactam/ampicillin, together with an assessment of its tolerability and safety in the treatment of gynaecological and obstetric infections. A total of 30 women with pelvic inflammatory disease, wound infections, vaginitis and puerperal sepsis received an intramuscular combination of sulbactam/ampicillin in a total daily dose of 1.5 g for between 3 and 7 days. Clinical cure and improvement were achieved in 27 (90%) cases but there was no response in three (10%) cases. No side-effects were seen in 29 (97%) cases, whereas tolerable local injection site pain was reported in one case. The safety of the sulbactam/ampicillin antibiotic combination was evident in all the cases studied, as there was no significant difference between the means of laboratory tests before and after therapy of blood and renal measures.

Topics: Adult; Ampicillin; Bacterial Infections; Drug Therapy, Combination; Female; Genital Diseases, Female; Humans; Injections, Intramuscular; Sulbactam